Clearside Biomedical (CLSDQ) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
14 Jan, 2026Executive summary
Positive Phase 2b Odyssey trial results for CLS-AX in wet AMD met all primary and secondary endpoints, demonstrating strong efficacy, safety, and flexible redosing, supporting advancement to Phase 3.
Suprachoroidal delivery platform validated by commercial and clinical partnerships, including new collaborations in Asia-Pacific, Santen, Arctic Vision, and major pharma companies.
XIPERE is the first FDA-approved product for uveitic macular edema; ARVN001 (XIPERE) is under regulatory review in Australia and Singapore.
Key management changes include Tony Gibney as Board Chair and expanded responsibilities for Victor Chong; Dr. Glenn Yiu joined the Scientific Advisory Board.
Net loss for Q3 2024 was $7.7 million, improved from $9.3 million in Q3 2023; nine-month net loss was $27.0 million.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $23.6 million as of September 30, 2024, expected to fund operations into Q3 2025.
Q3 2024 revenue was $1.0 million, up from $0.9 million in Q3 2023; nine-month revenue was $1.4 million, down from $1.9 million year-over-year.
Research and development expenses decreased to $4.1 million in Q3 2024 from $5.1 million in Q3 2023, mainly due to lower CLS-AX program costs.
General and administrative expenses rose to $2.8 million in Q3 2024 from $2.6 million in Q3 2023, driven by higher patent and consulting fees.
Net cash used in operations was $19.4 million for the nine months ended September 30, 2024.
Outlook and guidance
Planning two Phase 3 trials for CLS-AX in wet AMD, with an End-of-Phase 2 FDA meeting expected in early 2025 and trial initiation targeted for the second half of 2025.
Ongoing research to advance small molecule candidates for geographic atrophy, with IND timing yet to be determined.
Expects continued operating losses and negative cash flows until significant milestone or royalty revenue is generated.
Additional Odyssey data to be presented at upcoming medical conferences in Asia, Europe, and the US.
Additional capital will be required to complete CLS-AX development and other programs.
Latest events from Clearside Biomedical
- Suprachoroidal delivery platform advances with strong clinical data and key late Q3 2024 milestones.CLSDQ
Status Update3 Feb 2026 - CLS-AX maintained vision, reduced injections by 84%, and showed strong safety in wet AMD.CLSDQ
Study Result19 Jan 2026 - Flexible, safe suprachoroidal dosing in wet AMD sets up broad phase III launch in 2025.CLSDQ
Stifel 2024 Healthcare Conference13 Jan 2026 - CLS-AX advances to phase 3, leveraging flexible dosing and suprachoroidal delivery for wet AMD.CLSDQ
Oppenheimer 35th Annual Healthcare Life Sciences Conference 202524 Dec 2025 - FDA-aligned phase III CLS-AX trials advance as cash supports operations into late 2025.CLSDQ
Q4 202424 Dec 2025 - Key votes include director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQ
Proxy Filing2 Dec 2025 - Proxy covers director elections, say-on-pay, auditor ratification, and doubling authorized shares.CLSDQ
Proxy Filing2 Dec 2025 - Vote sought on reverse stock split and share reduction to maintain Nasdaq listing.CLSDQ
Proxy Filing2 Dec 2025 - Vote sought on reverse stock split and share reduction to maintain Nasdaq listing compliance.CLSDQ
Proxy Filing2 Dec 2025